IM has received increased attention due to the occurrence of adverse events following gamma-retroviral vector-based gene therapy to correct the X-linked severe combined immunodeficiency disease (X-SCID) in which a lymphoproliferative disorder was induced in patients by activation of the LMO2 oncogene [10-13]. This evidence concerns the gene LMO2 and severe combined immunodeficiency.